Pfizer $4.9 billion cash acquisition of Metsera, a clinical-stage biotech focused on next-generation obesity drugs, is more than another high-profile deal in pharma’s dealmaking spree. It signals a ...
Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...
Pfizer delivered a significant earnings surprise in its third-quarter results, demonstrating the pharmaceutical giant’s resilience amid a challenging year for its stock performance. The company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback